Windlas Biotech Ltd
₹755
(-1.35%)
Mon, 02 Mar 2026, 01:48 pm
Health Technology
Pharmaceuticals: Major
24.5KWindlas Biotech EV/EBITDA Ratio
| Particulars | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 11.31 | 11.43 | 18.38 | 36.07 |
| Price to book ratio | 0 | 0 | 0 | 0 | 1.16 | 1.17 | 2.37 | 4.31 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0.93 | 0.95 | 1.70 | 2.90 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 41.90 | 7.53 | 9.76 | 33.62 |
| Enterprise value | 0 | 0 | 0 | 0 | 2.59B | 3.6B | 8.69B | 19.93B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 4.98 | 5.95 | 11.04 | 21.05 |
| Debt to equity ratio | 0.46 | 0.16 | 0.14 | 0.16 | 0.02 | 0.01 | 0.01 | 0.06 |
| Return on equity % | 0 | 40.06 | 8.04 | 7.75 | 12.83 | 10.70 | 13.66 | 12.76 |
Windlas Biotech Ltd Enterprise Value to EBITDA Ratio
The Windlas Biotech Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Windlas Biotech Ltd's valuation, profitability, and overall financial performance. Tracking the Windlas Biotech Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Windlas Biotech Ltd (NSE: WINDLAS, BSE: 543329) is currently trading at ₹755, with a market capitalization of ₹15.98B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Windlas Biotech Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Windlas Biotech Ltd Enterprise Value to EBITDA Ratio Current Value
The current Windlas Biotech Ltd Enterprise Value to EBITDA Ratio stands at 21.05.
The latest Windlas Biotech Ltd Enterprise Value to EBITDA Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Windlas Biotech Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Windlas Biotech Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 21.05
- 2023: 11.04
- 2022: 5.95
- 2021: 4.98
- 2020: 0
The recent rise in Windlas Biotech Ltd Enterprise Value to EBITDA Ratio suggests strengthening valuation trends and improving market sentiment.
What Windlas Biotech Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Windlas Biotech Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Windlas Biotech Ltd.
Windlas Biotech Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Windlas Biotech Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Windlas Biotech Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Windlas Biotech Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800